Xinjunte Snags ￥10M in Series A Funding Round, Focusing on Orthopedic Surgery Robots

According to 36Kr.com, Shenzhen Xinjunte Intelligent Medical Devices Co., Ltd. ("Xinjunte"), a company engaged in the R&D and production of orthopedic surgical robots, has completed its series A financing of tens of millions yuan, led by Morningside Venture Capital, with participation from the existing investor Highlight Capital, and Healthcare Capital as the exclusive financial advisor for this financing. 

Previously, Xinjunte has got investment from Bloomage International, Highlight Capital, Morale Capital, Zhongguancun Mutual Fund and other investment institutions.

Founded in 2015, Xinjunte focuses on the research and development of intelligent medical devices for bone surgery. The company's main product for the integration of preoperative planning, intraoperative navigation, and the terminal execution, is the intelligent multi-function operation system called "ORTHBOT". The robot uses special mechanical arms to help doctors complete a large number of difficult and high-risk operations, making the operation more accurate, efficient and safer.

Xinjunte has successfully completed clinical trials of ORTHBOT in 2018. According to Jiang Liwei, the chairman of Xinjunte, ORTHBOT is expected to be approved for the market in the next 12 months and can be sold to first-class hospitals, regional medical centers, orthopedic hospitals, and county-level hospitals.

Morningside is one of China's earliest early-stage venture investors with around US$1.7 billion under management including four USD funds and one RMB fund, from the commitment of sovereign wealth funds, family offices, fund of funds, university endowments, etc.  The firm prides itself on not only providing insight and industry experience but also mental and operational support.

HLC is a health industry focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.) and consumer health (hospital chains, personal care, etc.).